FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is application of endothelin, selected from group, including darusentan, ambrisentan, {5-(4-bromphenyl)-6-[2-(5-brompyrimidin-2-yloxy)ethoxy]pyrimidin-4-yl}amide of propylsulfamonic acid, and bosentan (Tracleer®) for preparation of medication intended for treatment of early stage of idiopathic pulmonary fibrosis (IPF), where change by type of "cell lung" on HRCT or CT - scans is either absent or is minimal. It is shown that claimed antagonists of endothelin receptor completely inhibit ET-1-induced collagen synthesis, bringing it to initial level.
EFFECT: demonstrated is maximal efficiency of bosentan in prevention of clinical IPF aggravation in patients with early stage of disease.
9 cl, 4 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION AND LUNG INJURY | 2013 |
|
RU2718055C2 |
| APPLICATION OF SANGLIFERIN FOR TREATING HEPATITIS C VIRUS | 2006 |
|
RU2427372C2 |
| PYRIMIDINESULPHAMIDES AND THEIR USE AS ANTAGONISTS OF ENDOTHELIAL RECEPTORS | 2003 |
|
RU2329255C2 |
| THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN | 2009 |
|
RU2519161C2 |
| APPLICATION OF ORGANIC COMPOUNDS | 2005 |
|
RU2426532C2 |
| COMBINATION THERAPY OF PULMONARY HYPERTENSION | 2016 |
|
RU2780758C2 |
| DERIVATIVES OF ISOTHIOUREA AND METHOD OF THEIR PRODUCTION, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITION | 2005 |
|
RU2376297C2 |
| METHODS OF TREATING PULMONARY HYPERTENSION | 2012 |
|
RU2599490C2 |
| METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | 2017 |
|
RU2765737C2 |
| COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | 2009 |
|
RU2503672C2 |
